ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 203 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $0 | -100.0% | 24 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 24 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | -75.0% | 24 | -64.2% | 0.00% | -100.0% |
| Q4 2020 | $4,000 | +33.3% | 67 | -11.8% | 0.00% | – |
| Q3 2020 | $3,000 | -40.0% | 76 | -32.1% | 0.00% | – |
| Q2 2020 | $5,000 | -96.3% | 112 | -96.5% | 0.00% | -100.0% |
| Q1 2020 | $136,000 | -49.8% | 3,245 | -48.6% | 0.01% | -35.3% |
| Q4 2019 | $271,000 | +22.6% | 6,311 | +2.2% | 0.02% | +13.3% |
| Q3 2019 | $221,000 | +2662.5% | 6,176 | +2051.9% | 0.02% | +1400.0% |
| Q2 2019 | $8,000 | -70.4% | 287 | -71.6% | 0.00% | -50.0% |
| Q1 2019 | $27,000 | -52.6% | 1,010 | -72.0% | 0.00% | -60.0% |
| Q4 2018 | $57,000 | +850.0% | 3,609 | +1222.0% | 0.01% | – |
| Q3 2018 | $6,000 | +100.0% | 273 | +120.2% | 0.00% | – |
| Q1 2018 | $3,000 | -25.0% | 124 | 0.0% | 0.00% | – |
| Q4 2017 | $4,000 | – | 124 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |